Liraglutide Cost in Maine 2026: Cash Price, Medicaid, Insurance, and Compounding Options

What Is Liraglutide and Why Does the Price Vary So Much in Maine?

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk and sold under two brand names: Victoza (1.2 mg or 1.8 mg daily for type 2 diabetes) and Saxenda (up to 3.0 mg daily for chronic weight management). The FDA approved Victoza in January 2010 and Saxenda in December 2014. [1] Both are prescription-only subcutaneous injections administered once daily.

Price variation in Maine comes from several layers of the drug supply chain. The Novo Nordisk manufacturer list price sits at $1,349/month. Maine retail pharmacies, after standard wholesale discounts, average around $900/month for cash-pay patients in 2026. Patients with commercial insurance, Medicaid, or manufacturer savings programs can pay far less. And patients who qualify for compounded liraglutide through a licensed 503A pharmacy in Maine may pay as little as $150/month, though availability depends on pharmacy-specific compounding capacity and prescriber authorization.

The SCALE Obesity trial (N=3,731), published in the New England Journal of Medicine in 2015, established liraglutide 3.0 mg as clinically meaningful for weight reduction: participants lost a mean of 8.4% of body weight at 56 weeks versus 2.8% in the placebo group (P<0.001). [2] That efficacy data drives high demand, which in turn keeps brand-name prices elevated even as the broader GLP-1 market expands.

Clinicians and patients navigating Maine's pharmacy field benefit from understanding each pricing tier before deciding on a therapy pathway.

Maine Retail Cash Prices for Liraglutide in 2026

The average cash-pay price at Maine retail pharmacies is approximately $900/month for a 30-day supply of liraglutide at therapeutic doses. That figure reflects 2026 pharmacy acquisition costs after standard wholesale markups but before any discount card, coupon, or assistance program is applied.

Novo Nordisk's published list (WAC) price is $1,349/month. [1] The gap between WAC and retail cash price exists because many pharmacies negotiate modest direct discounts, and because GoodRx-style discount cards have become standard at checkout for uninsured patients. Prices at Maine's independent rural pharmacies may differ from large chain pharmacy pricing by $50 to $150 per month in either direction, so calling ahead is always worthwhile.

For patients without insurance, the most effective cost-reduction tools are:

• Novo Nordisk Patient Assistance Program (PAP). Uninsured patients with household income at or below 400% of the federal poverty level may qualify for free or deeply discounted medication directly from Novo Nordisk. Applications are processed at NovoCare. [3]
• Prescription discount cards. GoodRx, RxSaver, and similar services sometimes reduce the retail price to $700 to $850/month at participating Maine pharmacies, though exact amounts vary by location.
• 340B program. Maine has multiple federally qualified health centers (FQHCs) and rural health clinics enrolled in the 340B Drug Pricing Program. Eligible low-income patients receiving care at those sites may access liraglutide at 340B pricing, which can be substantially below retail. [4]

A 2023 JAMA Internal Medicine analysis of GLP-1 list prices found that WAC prices for GLP-1 receptor agonists in the United States exceeded those of peer nations by three to ten times, underscoring why out-of-pocket costs remain a barrier even for insured patients with high-deductible plans. [5]

Does MaineCare (Maine Medicaid) Cover Liraglutide?

MaineCare covers liraglutide for both type 2 diabetes management and chronic weight management, but prior authorization (PA) is required in both cases. Approval is not automatic, and the PA criteria differ depending on the indication.

For type 2 diabetes, prescribers typically must document that the patient has an established diagnosis, a recent HbA1c above a specified threshold (commonly 7.5% or higher per MaineCare policy), and that metformin or another first-line agent has been tried or is contraindicated. For chronic weight management under the Saxenda indication, MaineCare generally requires documentation of BMI <27 with a weight-related comorbidity or BMI of 30 or higher, along with evidence of a structured lifestyle intervention. [6]

The American Diabetes Association's 2024 Standards of Care in Diabetes state that "GLP-1 receptor agonists should be considered for patients with type 2 diabetes who need to minimize hypoglycemia, lose weight, or reduce cardiovascular risk." [7] Maine's PA criteria align broadly with that guidance, though the specific formulary tier and step-therapy requirements should be confirmed directly with the prescribing clinician or by calling MaineCare member services at 1-800-977-6740.

PA approval timelines in Maine typically run three to seven business days for standard reviews. Urgent or expedited PA requests, when medically justified, must be resolved within 72 hours under federal Medicaid rules. [8] Denials can be appealed, and many are overturned when the prescriber submits additional clinical documentation.

Patients enrolled in MaineCare managed care plans (such as those administered by Anthem or WellCare of Maine) follow the same PA framework but should verify the specific formulary, because managed care organizations sometimes apply more restrictive criteria than the base MaineCare fee-for-service program.

Which Commercial Insurance Plans Cover Liraglutide in Maine?

Coverage across Maine's commercial insurance market is inconsistent. Most large employer-sponsored plans in Maine cover Victoza (the diabetes indication) at Tier 3 or Tier 4, meaning patient cost-sharing after insurance can still run $100 to $300/month depending on the plan's deductible and out-of-pocket maximum. Saxenda (the weight management indication) faces greater resistance: a meaningful share of commercial plans in Maine still exclude it or require step therapy through older agents first.

The Affordable Care Act's preventive services mandate does not currently require commercial insurers to cover obesity pharmacotherapy, leaving coverage decisions to individual plan design. [9] Maine-specific fully insured plans must comply with state insurance regulations set by the Maine Bureau of Insurance, but those regulations do not mandate GLP-1 coverage for weight management as of mid-2025.

Practical steps for Maine patients with commercial insurance:

1. Ask your pharmacist to run a real-time benefits check before filling.
2. Request a formulary exception letter from your prescriber if the plan excludes liraglutide or requires step therapy through an agent your clinician considers inappropriate.
3. Check whether your plan's specialty pharmacy network offers lower cost-sharing for injectable medications.

The Novo Nordisk savings card for Victoza and Saxenda can reduce cost-sharing to as low as $25 to $99/month for eligible commercially insured patients, but it cannot be used in combination with any federal or state government insurance program including MaineCare, Medicare, or Medicaid. [3] Maine patients on Medicare Part D face the Medicare coverage gap and should ask their plan about Extra Help (Low Income Subsidy) eligibility. [10]

Is Compounded Liraglutide Legal in Maine?

Compounded liraglutide is legally available in Maine through state-licensed 503A compounding pharmacies operating under the federal Drug Quality and Security Act and Maine Board of Pharmacy rules. At roughly $150/month, it is the most affordable route for cash-pay patients who cannot access brand-name programs.

A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. [11] Compounded liraglutide is not FDA-approved and has not undergone the same manufacturing quality reviews as Victoza or Saxenda, so patients should only use pharmacies that can document USP <797> compliance for sterile compounding, third-party potency testing of each batch, and state licensure in Maine.

The FDA's guidance on compounding and the shortage list is worth understanding here. During periods when brand-name semaglutide was on the FDA drug shortage list, 503A pharmacies could compound semaglutide more broadly. Liraglutide itself was not on the FDA shortage list as of early 2025, [12] which means 503A compounding of liraglutide is permissible but subject to the standard patient-specific prescription requirement rather than the broader shortage-list permissions. Prescribers in Maine must write a prescription for a specific identified patient; a pharmacy cannot compound liraglutide for general stock.

The Maine Board of Pharmacy maintains a public license verification database. Before using any compounding pharmacy, confirm the pharmacy's active Maine license and ask specifically whether they perform in-process and finished-product sterile testing. The FDA issued a safety communication in 2024 noting that compounded GLP-1 products from facilities with inadequate quality controls had resulted in dosing errors and adverse events. [13] Vetting your pharmacy is not optional.

Can Maine Patients Get Liraglutide Through Telehealth?

Yes. Telehealth prescribing of liraglutide is fully legal in Maine for both type 2 diabetes and chronic weight management. Maine law requires that prescribers establish a valid patient-provider relationship before issuing a prescription, but that relationship can be established through synchronous video visits. [14]

Maine's telehealth parity law (Title 24-A, Section 4316) requires commercial insurers that cover a service in person to also cover it via telehealth. This means a MaineCare or commercially insured patient who would be covered for an endocrinology or primary care visit in person should also have that visit covered via video. Reimbursement specifics vary by plan, and some require that telehealth visits occur with a Maine-licensed provider.

HealthRX's telehealth platform operates in Maine and connects patients with board-certified clinicians who can evaluate eligibility for liraglutide, submit prior authorization documentation to MaineCare or commercial insurers, and coordinate with a licensed Maine pharmacy or a vetted 503A compounder for prescription fulfillment.

A 2022 New England Journal of Medicine review of telehealth prescribing for obesity pharmacotherapy found that asynchronous and synchronous telehealth visits produced similar rates of medication initiation compared to in-person visits for weight management drugs. [15] Remote access therefore does not appear to compromise clinical quality for this class of medication.

How Liraglutide Dosing Affects Total Monthly Cost

The starting dose of liraglutide for weight management (Saxenda) is 0.6 mg/day for one week, escalating by 0.6 mg weekly to a maintenance dose of 3.0 mg/day. For type 2 diabetes (Victoza), the maintenance dose is typically 1.2 mg or 1.8 mg/day. [1]

Lower doses during titration use less drug per month, so patients in their first four to five weeks of therapy spend slightly less than the full monthly maintenance cost. A patient titrating from 0.6 mg to 3.0 mg over five weeks consumes approximately 60% of a full month's supply of 3.0 mg pens before reaching maintenance. At the $900/month retail cash price for a 3.0 mg supply, first-month drug costs may run closer to $540 depending on which pen strengths are dispensed.

This titration detail matters when calculating realistic out-of-pocket costs for new starters and when presenting savings-card copay assistance calculations to commercial insurers. The Novo Nordisk NovoCare team can clarify copay card maximums for the titration period.

A 2021 Diabetes Care study (N=412) examining real-world liraglutide persistence found that approximately 44% of patients remained on therapy at 12 months, with cost cited as the primary reason for discontinuation by 38% of those who stopped. [16] Maine clinicians who proactively connect patients with PAP and PA resources at initiation may see meaningfully better 12-month adherence rates.

Comparing Liraglutide to Semaglutide in Maine: Cost and Efficacy Context

Some Maine patients and clinicians ask whether semaglutide (Ozempic for diabetes, Wegovy for weight management) is a better choice than liraglutide. The short answer on efficacy: semaglutide generally produces greater weight loss. STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% placebo. [17] SCALE Obesity showed liraglutide 3.0 mg produced 8.4% weight loss at 56 weeks versus 2.8% placebo. [2]

On cost in Maine in 2026, brand-name semaglutide list prices are slightly higher than liraglutide, and compounded semaglutide availability depends on FDA shortage-list status, which has changed repeatedly. Compounded liraglutide at $150/month may remain more consistently available than compounded semaglutide for Maine cash-pay patients during periods when semaglutide is removed from the shortage list.

The HealthRX clinical team uses a three-tier decision framework for Maine GLP-1 candidates:

Tier 1 (Insured, PA likely approved). Pursue brand-name semaglutide or liraglutide through the patient's insurance with manufacturer copay card stacked on top. Aim for <$99/month out-of-pocket.

Tier 2 (Uninsured, income-qualified). Apply to Novo Nordisk PAP or access the 340B program through a qualifying Maine FQHC. Target $0 to $25/month.

Tier 3 (Uninsured, income above PAP threshold, cash-pay). Prescribe compounded liraglutide through a Maine-licensed, USP <797>-compliant 503A pharmacy. Target $150/month, with step-up to brand-name if insurance is obtained.

Practical Steps for Maine Patients Starting Liraglutide in 2026

Getting liraglutide in Maine is a multi-step process. Each step has a concrete action:

1. Schedule a prescriber visit. In-person or telehealth with a Maine-licensed clinician. Bring recent labs: HbA1c, fasting glucose, lipid panel, and BMI documentation if seeking the weight management indication.

2. Ask for a prior authorization at the first visit. Do not wait until the pharmacy denies the claim. PA paperwork takes days; starting it at visit one reduces delays.

3. Identify your payment pathway before leaving the visit. MaineCare PA, commercial insurance tier, PAP application, or 503A compounded prescription. Each pathway requires different forms.

4. Verify pharmacy licensure. For compounded liraglutide, check the Maine Board of Pharmacy license database and ask the pharmacy for their most recent USP <797> audit or third-party sterility/potency certificate.

5. Begin titration and schedule a four-week follow-up. Gastrointestinal side effects (nausea in up to 40% of patients per the SCALE trial) [2] are most common during titration. Early follow-up allows dose adjustment or anti-nausea support if needed.

A 2020 Annals of Internal Medicine systematic review of GLP-1 therapy for obesity (N=15 trials, 7,234 participants) found that structured support during the titration phase was associated with higher rates of reaching maintenance dose. [18] Maine clinicians who offer a structured titration check-in, even via brief telehealth message, may reduce early discontinuation.

Maine-Specific Resources for Liraglutide Access

Several state and federal resources are directly relevant to Maine liraglutide patients:

• Maine DHHS MaineCare member services. 1-800-977-6740. Ask specifically about prior authorization for GLP-1 medications under the obesity or diabetes benefit.
• Maine 340B-covered FQHCs. Includes Penobscot Community Health Care, Nasson Health Care, and Portland Community Health Center, among others. HRSA's 340B database lists all covered entities. [4]
• NovoCare (Novo Nordisk patient support). 1-888-668-6463. Handles PAP applications and savings card enrollment for Victoza and Saxenda. [3]
• Maine Board of Pharmacy license search. Verify any compounding pharmacy before use.
• HealthRX telehealth platform. Maine-licensed clinicians available for video visits, PA support, and ongoing GLP-1 management.

The CDC's 2023 National Diabetes Statistics Report estimates that 11.1% of the U.S. Adult population has diagnosed diabetes, with Maine's adult diabetes prevalence at approximately 9.4%. [19] At that prevalence, tens of thousands of Maine adults may qualify for liraglutide under the diabetes indication alone, making access and cost clarity a public health priority.

For MaineCare patients approved through prior authorization, liraglutide copays are governed by MaineCare cost-sharing rules, which cap most prescription copays at $4 per fill for beneficiaries above the nominal income threshold. That makes MaineCare the lowest-cost pathway for eligible Maine residents, well below even the $150/month compounded option.